Sientra (SIEN) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SIEN shares.
View SIEN analyst ratings or view top-rated stocks.

3 brokerages have issued 1 year price objectives for Sientra's stock. Their SIEN share price forecasts range from $5.00 to $10.00. On average, they expect the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 167.9% from the stock's current price.
View analysts price targets for SIEN or view top-rated stocks among Wall Street analysts.

Sientra's stock was trading at $2.0290 on January 1st, 2023. Since then, SIEN stock has increased by 38.0% and is now trading at $2.80.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our SIEN earnings forecast.

Sientra, Inc. (NASDAQ:SIEN) released its earnings results on Thursday, August, 10th. The medical instruments supplier reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. The medical instruments supplier earned $23.13 million during the quarter, compared to analyst estimates of $25 million. Sientra had a negative trailing twelve-month return on equity of 1,078.78% and a negative net margin of 64.02%.

Sientra's stock reverse split on the morning of Monday, January 23rd 2023. The 1-10 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Sientra updated its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $98.00 million-$102.00 million, compared to the consensus revenue estimate of $104.51 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sientra investors own include Rigel Pharmaceuticals (RIGL), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Miragen Therapeutics (MGEN), Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX), Micron Technology (MU) and Novavax (NVAX).

Sientra trades on the NASDAQ under the ticker symbol "SIEN."

Sientra's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wells Fargo & Company MN (2.83%), BlackRock Inc. (0.83%), Geode Capital Management LLC (0.82%), Renaissance Technologies LLC (0.42%), Stifel Financial Corp (0.39%) and State Street Corp (0.34%). Insiders that own company stock include Andrew C Schmidt, Andrew C Schmidt, Hove Caroline F Van, Oliver Christian Bennett, Paul Sean Little, Ronald Menezes and Valerie J Miller.
View institutional ownership trends.

Shares of SIEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SIEN stock can currently be purchased for approximately $2.80.

Sientra (NASDAQ:SIEN) has a market capitalization of $31.56 million and generates $90.55 million in revenue each year. The medical instruments supplier earns $-73,310,000.00 in net income (profit) each year or ($6.66) on an earnings per share basis.

The company employs 304 workers across the globe.

Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The official website for the company is www.sientra.com. The medical instruments supplier can be reached via phone at (805) 562-3500, via email at ir@sientra.com, or via fax at 805-562-8401.